Combinatorial effect of epirubicin and 5-fluorouracil in the treatment of temozolomide-resistant glioblastoma cells
Authors:
- Mehrsa BayatMBMehrsa Bayat
- Muhli̇s AkmanMAMuhli̇s Akman
- Türker KiliçTKTürker Kiliç
- Ti̇mUçi̇n AvşarTATi̇mUçi̇n Avşar
Open Access
- 21 April 2026
- journal article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 50 (2) , 170-184
Abstract
Background: Glioblastoma (GBM) is a highly aggressive form of brain tumor characterized by rapid proliferation and invasiveness. It is associated with a poor prognosis due to acquired resistance to temozolomide (TMZ). In this study, we investigated whether a combination of epirubicin, 5-fluorouracil (5-FU), and TMZ could improve TMZ sensitivity in resistant GBM cells and help overcome resistance.Materials and methods: TMZ resistance was established in the U87MG cell line. The MTT assay was used to measure cell viability. Reactive oxygen species (ROS) and apoptosis were measured using flow cytometry. RNA-seq was used to evaluate genomic changes based on treatment with drugs alone or in combination. Results: We demonstrated that the triple-drug combination significantly reduced cell viability. The biochemical pathways involved revealed that this combination therapy significantly increased the generation of ROS. The RNA-seq analysis indicated that combination therapy effectively suppressed cell cycle regulatory pathways, enhancing cell cycle arrest and promoting apoptosis in TMZ-resistant cells. Conclusion: These findings underscore the potential viability of integrating epirubicin and 5-FU with TMZ to improve therapeutic outcomes in patients suffering from chemoresistant GBM. These combination therapies could represent an important advance in the treatment of this challenging malignancy.Keywords
This publication has 50 references indexed in Scilit:
- Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanineOncogene, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-l-tyrosine and magnetic resonance spectroscopyJournal of Neurosurgery, 2005
- Epidemiology and etiology of gliomasActa Neuropathologica, 2005
- Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain BarrierCancer Research, 2004
- Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialJournal of Clinical Oncology, 2002
- Drugs ten years later: EpirubicinAnnals of Oncology, 1993
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.Journal of Clinical Oncology, 1988
- Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.Journal of Clinical Oncology, 1986